Roche has announced that it has terminated two phase III trials of crenezumab, a monoclonal antibody targeting beta-amyloid. The trials, CREAD 1 and CREAD 2, were evaluating the agent in prodromal to mild Alzheimer’s disease.
In the phase II ABBY trial, crenezumab failed to meet its primary endpoints of change from baseline in ADAS-cog12 and Clinical Dementia Rating-Sum of Boxes (CDR-SB) scores (Cummings et al. Neurology 2018;90:e1889-e1897). BLAZE, a second phase II neuroimaging study, also failed to meet its endpoint of change from baseline in amyloid burden (Salloway et al. Alzheimers Res Ther 2018;10:96). However, in ABBY, there was a trend to improvement in a milder subgroup and Roche wagered that a higher dose might be effective.